Exscientia Investors Sue Over CEO Misconduct After 23% Selloff

An AI drug-discovery company faces claims that it ripped off investors by failing to quickly address and disclose its CEO’s inappropriate work relations.

The suit against Exscientia Plc, an Oxford, England-based company, regards damages in shares acquired between March 23, 2022 to Feb. 12, 2024. The plaintiffs, including Frank Campanile and other investors, say they “would not have purchased or otherwise acquired said securities” from Exscientia if they had known the truth about its leadership, said a complaint filed June 21 in a US district court in the District of New Jersey.

CEO Andrew Hopkins was terminated nearly two years ...